BioCentury
ARTICLE | Company News

EC approves Orexigen's Mysimba

March 27, 2015 12:50 AM UTC

Orexigen Therapeutics Inc. (NASDAQ:OREX) said the European Commission approved an MAA for Mysimba naltrexone/ bupropion as an adjunct to reduced-calorie diet and increased physical activity to manage weight in adults who are obese or are overweight with weight-related comorbidities. Orexigen did not disclose a launch timeline and said it will seek commercialization partners outside of North America.

The company markets the drug as Contrave in the U.S.; sales were $6.5 million in 4Q14. ...